Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIV

The acquisition supports Glenmark’s goal of achieving carbon neutrality by 2030. The deal follows a Securities Subscription & Shareholder’s Agreement signed in May 2024 with O2 Renewable Energy XXIV and O2 Energy SG Pte. Ltd., involving an investment of Rs 1.99 crore through the purchase of equity shares and Compulsorily Convertible Debentures (CCDs).